Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor

ConclusionsAn increased frequency of genomic alterations is observed in UBCFGFR. These have been linked to immune checkpoint inhibitor resistance. Clinical trials are needed to evaluate UBCFGFR-based biomarkers prognostic of an immune checkpoint inhibitor response. Only then can we successfully incorporate novel therapeutic strategies into the evolving landscape of UBC treatment.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research